Glibenclamide

Concomitant administration of glyburide and bosentan is contraindicated due to increased risk of liver enzyme elevations.

Co-administration may cause severe hypoglycemia and fatalities have been reported due to potentiation of glucose-lowering effect.

Concomitant use potentiates glucose-lowering effect, with severe hypoglycemia and fatalities reported. Monitor blood glucose.

Co-administration may cause severe hypoglycemia and fatalities have been reported due to potentiation of glucose-lowering effect.

Colesevelam may decrease sulfonylurea exposure. Administer glyburide 4 hours prior to colesevelam.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Acitretin treatment potentiated the blood glucose-lowering effect of glyburide in some subjects. Careful supervision of diabetic patients is recommended.

Calcium channel blocking drugs may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

May potentiate hypoglycemic action of glyburide. Patient should be observed closely for hypoglycemia when administered and for loss of control when withdrawn.

Reduces glyburide AUC by 32% and Cmax by 47% when coadministered; effect depends on timing of administration.

Corticosteroids may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Glyburide may increase cyclosporine plasma concentration and potentially lead to its increased toxicity. Monitoring and dosage adjustment recommended.

May potentiate hypoglycemic action of glyburide. Patient should be observed closely for hypoglycemia when administered and for loss of control when withdrawn.

May produce hyperglycemia and lead to loss of control of blood glucose.

OATP1B1 substrate; eltrombopag may increase exposure. Monitor closely and consider dose reduction if appropriate.

OATP1B1 substrate; monitor for excessive exposure and consider dose reduction if appropriate.

Estrogens may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May potentiate hypoglycemic action of glyburide. Patient should be observed closely for hypoglycemia when administered and for loss of control when withdrawn.

Fluvastatin increases glyburide exposure. Monitor blood glucose levels when fluvastatin dose is changed.

Monitor blood glucose levels when fluvastatin is initiated.

OATP1B1 substrate; gemfibrozil inhibition may increase glyburide exposure, requiring dosing reduction.

Isoniazid may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May potentiate hypoglycemic action of glyburide resulting in severe hypoglycemia.

May potentiate hypoglycemic action of glyburide. Patient should be observed closely for hypoglycemia when administered and for loss of control when withdrawn.

Single-dose study showed variable decreases in glyburide AUC and Cmax; clinical significance uncertain. Steady-state coadministration showed no pharmacokinetic/pharmacodynamic changes.

Coadministration resulted in decreases in glyburide AUC and Cmax that were highly variable. Clinical significance uncertain due to single-dose study design and lack of correlation between glyburide blood levels and pharmacodynamic effects.

Co-administration of miglitol with glyburide resulted in 8-25% lower glyburide AUC and Cmax values across multiple studies, though differences were not consistently statistically significant.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Nicotinic acid may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

May potentiate hypoglycemic action of glyburide. Close observation for hypoglycemia recommended.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Oral contraceptives may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Phenothiazines may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Phenytoin may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

May worsen glucose control of glyburide by significantly inducing metabolic isozymes.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

DIACOMIT may inhibit BCRP transport of glyburide; consider dose reduction if adverse reactions occur.

BACTRIM potentiates oral hypoglycemic effects of glyburide. Additional blood glucose monitoring warranted.

Thiazides may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Thyroid products may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Decreases glyburide Cmax by 22% and AUC by 25%; monitor for loss of glycemic control.

Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.

No clinically significant pharmacokinetic interactions were observed when coadministered with valsartan.

Antidiabetic Agents (e.g., Insulin, Glyburide/Glibenclamide) Since disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concurrently with quinolones and an antidiabetic agent, careful monitoring of blood glucose is recommended when these agents are used concomitantly (see PRECAUTIONS, General and Information for Patients ).

BCRP substrate. In vitro studies suggest pretomanid may inhibit BCRP, potentially increasing glyburide exposure. Clinical impact unknown; monitor for adverse reactions.

Other Drugs : Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen.